189 related articles for article (PubMed ID: 30730305)
1. uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.
Wei C; Li J; Adair BD; Zhu K; Cai J; Merchant M; Samelko B; Liao Z; Koh KH; Tardi NJ; Dande RR; Liu S; Ma J; Dibartolo S; Hägele S; Peev V; Hayek SS; Cimbaluk DJ; Tracy M; Klein J; Sever S; Shattil SJ; Arnaout MA; Reiser J
J Clin Invest; 2019 Apr; 129(5):1946-1959. PubMed ID: 30730305
[TBL] [Abstract][Full Text] [Related]
2. c-Src is in the effector pathway linking uPAR and podocyte injury.
Kopp JB; Heymann J
J Clin Invest; 2019 Apr; 129(5):1827-1829. PubMed ID: 30939121
[TBL] [Abstract][Full Text] [Related]
3. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
4. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases.
Kim EY; Hassanzadeh Khayyat N; Dryer SE
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3527-3536. PubMed ID: 30293571
[TBL] [Abstract][Full Text] [Related]
7. MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes.
Lang Y; Zhao Y; Zheng C; Lu Y; Wu J; Zhu X; Zhang M; Yang F; Xu X; Shi S; Liu Z
Cell Death Dis; 2019 May; 10(6):401. PubMed ID: 31127093
[TBL] [Abstract][Full Text] [Related]
8. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
9. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
10. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Zhang B; Xie S; Shi W; Yang Y
Nephrol Dial Transplant; 2012 May; 27(5):1746-55. PubMed ID: 22076430
[TBL] [Abstract][Full Text] [Related]
11. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
Zhang B; Shi W; Ma J; Sloan A; Faul C; Wei C; Reiser J; Yang Y; Liu S; Wang W
J Mol Med (Berl); 2012 Dec; 90(12):1407-20. PubMed ID: 23015147
[TBL] [Abstract][Full Text] [Related]
12. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
[TBL] [Abstract][Full Text] [Related]
13. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
[TBL] [Abstract][Full Text] [Related]
14. RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.
Kim EY; Dryer SE
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166186. PubMed ID: 34166766
[TBL] [Abstract][Full Text] [Related]
15. Serum suPAR in patients with FSGS: trash or treasure?
Maas RJ; Deegens JK; Wetzels JF
Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
Hahm E; Wei C; Fernandez I; Li J; Tardi NJ; Tracy M; Wadhwani S; Cao Y; Peev V; Zloza A; Lusciks J; Hayek SS; O'Connor C; Bitzer M; Gupta V; Sever S; Sykes DB; Scadden DT; Reiser J
Nat Med; 2017 Jan; 23(1):100-106. PubMed ID: 27941791
[TBL] [Abstract][Full Text] [Related]
17. Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.
Pereira LHM; da Silva CA; Monteiro MLGDR; Araújo LS; Rocha LP; Reis MBDR; Ramalho FS; Corrêa RRM; Silva MV; Reis MA; Machado JR
PLoS One; 2019; 14(6):e0217569. PubMed ID: 31188898
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
[TBL] [Abstract][Full Text] [Related]
19. suPAR and chronic kidney disease-a podocyte story.
Zeier M; Reiser J
Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
[TBL] [Abstract][Full Text] [Related]
20. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
